| Project/Area Number |
21590853
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Hiroyuki 札幌医科大学, 医学部, 講師 (40332910)
IMAI Kohzoh 東京大学, 医科学研究所, 教授 (60117603)
SHINOMURA Yasuhisa 札幌医科大学, 医学部, 教授 (90162619)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 肝臓学 / 肝癌 / 抗体治療 / 分子標的 / 分子改変 / 癌 |
|---|
| Research Abstract |
For advanced hepatocellular carcinoma has not been established at all treatments, we' ve been doing this research for the purpose of development of therapeutic antibodies as ideal therapeutic agents. We have shown that interferon(IFN)-α/βinduced the up-regulation of fibroblast growth factor receptor-1(FGFR-1) expression in several human liver cancer cells. Based on this result, we have created several anti-FGFR-1 monoclonal antibodies(MoAbs). We revealed that the efficacy of combined treatment with anti-FGFR-1 MoAb and interferon-α/βin human liver cancer cells in vitro and in vivo. The aim of this antibody therapy is more potent anti-cancer effects, we performed molecular alterations of this antibody, and established a tri-functional specific antibody in this study.
|
